TABLE 1.
Susceptibilities of the isolates investigated g
| Strain | MEM MIC (µg/mL) a | C/T MIC (µg/mL) b | CZA MIC (µg/mL) a | CST MIC (µg/mL) c | FDC MIC (µg/mL) d | DD (mm) e | PAP-AUC |
|---|---|---|---|---|---|---|---|
| PAO1 | ND | ND | ND | ND | 0.25 | 31 | 40.63 |
| hR control | ND | ND | ND | ND | 1 | 21 | 124.9 |
| BSL5 | >8 | >256 | 48 | 4 | 2 | 26 | 45.35 |
| BSL9 | >8 | >256 | ND f | 4 | 4 | 24 | 90.58 |
| BSL15 | >8 | >256 | ND f | 4 | >32 | 13 | 158.9 |
a
Clinical microbiology laboratory.
b
Research laboratory, gradient diffusion strip.
c
Research laboratory, broth microdilution in cation adjusted Mueller-Hinton.
d
Research laboratory, broth microdilution in iron-depleted Mueller-Hinton media.
e
Kirby-Bauer disk diffusion zone diameter, in millimeters.
f
Presumed resistant.
g
C/T, ceftolozane-tazobactam; CZA, ceftazidime-avibactam; CST, colistin; FDC, cefiderocol; hR, heteroresistant; MEM, meropenem; PAP-AUC, population analysis profile-area under the curve; ND, not determined.